Adherium Annual Report

/in

Link to Full Report

Read more

CalciMedica Announces Peer-Reviewed Publication of Positive COVID-19 Data and Initiation of Blinded, Placebo-Controlled Trial of Auxora™ in Patients with Severe COVID-19 Pneumonia

/in

Link to Full Article Study published in Critical Care journal shows patients with severe COVID-19 pneumonia treated with Auxora and standard of care had substantially improved outcomes compared to patients on standard of care alone Clinical trial to enroll up to 400 patients at sites across the U.S., including California, Texas and Louisiana, is being […]

Read more

Destiny Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today

/in

Link to Full Article Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton. The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards […]

Read more

Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update

/in

Link to Full Article MARINA DEL REY, Calif., Aug. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the second quarter of 2020 and provided a corporate and clinical update. During the […]

Read more

Destiny Pharma’s positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections

/in

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive interim safety review of Phase 2b clinical trial of lead asset XF-73 in the prevention of post-surgical bacterial infections Brighton, United Kingdom – 11 August 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Read more

Adherium appoints Mr Geoff Feakes as Chief Technology Officer

/in

Link to Full Article Melbourne, Australia – 5 August 2020: Adherium Limited (ASX: ADR) a leader in digital inhaled device adherence, remote monitoring and data management solutions, has appointed Mr Geoff Feakes as Chief Technology Officer (CTO) leading the Company’s R&D and Innovation teams supporting Adherium’s revised business strategy. Mike Motion, Adherium CEO noted: “I […]

Read more